La catena delle opzioni mostra i dati chiave delle opzioni azionarie di  a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ..

 (OTC:ISBNF) Azioni, Catena delle Opzioni

<p>UBS  analyst Douglas Harter   maintains Claros Mortgage Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMTG#NYSE">CMTG</a>) with a Neutral and lowers the price target from $8.5 to $8.</p>


News

Price Target

Analyst Ratings

CMTG

UBS Maintains Neutral on Claros Mortgage Trust, Lowers Price Target to $8

WIIM

OPTX

Syntec Optics Holdings shares are trading lower after the company reported a year-over-year decline in Q3 EPS results.

Earnings

SGML

CORRECTION: Sigma Lithium Q3 EPS $(0.23) Misses $0.07 Estimate, Sales $20.89M Miss $72.54M Estimate

<p><strong>Ripple&#8217;s </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) rally is increasingly gaining momentum amid whale accumulation and increased optimism from traders.</p>
<p><strong>What Happened: </strong>XRP surged 22% on Friday, bringing its seven-day gains to 57%. The seventh-biggest cryptocurrency in the world has outperformed the two cryptos over the past week.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>24-Hour Trend</strong></td>
<td><strong>7-Day Trend</strong></td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td> $0.8786</td>
<td>$50 billion</td>
<td>&nbsp;22.2%</td>
<td>&nbsp;+58.9%</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$88,310.05</td>
<td>$1.75 trillion</td>
<td>&nbsp;-0.8%</td>
<td>&nbsp;+15.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td><strong> </strong>$3,029.91</td>
<td>$364.9 billion</td>
<td>&nbsp;-2%</td>
<td>&nbsp;+3.4%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes:</strong> In a <a href="https://x.com/santimentfeed/status/1857139322614603835">podcast</a> update, vetern crypto trader DonAlt identified XRP as being in a monthly breakout phase. </p>
<p>He highlighted resistance levels at $1.50 (2x the current price) and $3.60 (4x). </p>
<p>While not a fan of XRP fundamentally, he sees it as a strong trading opportunity. DonAlt also predicts the return of 2017-era traders who feel comfortable trading XRP.</p>
<p>In his latest <a href="https://x.com/CryptoDonAlt/status/1856379131870539963">tweet</a>, DonAlt stated that Dogecoin and XRP are the retail coins of old, outlining his entry levels for trading the altcoin.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">If all goes well and <a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> does a lot of crime these are the levels I&#39;m looking at <a href="https://t.co/sW49QLkKBx">pic.twitter.com/sW49QLkKBx</a></p>
<p>&mdash; DonAlt (@CryptoDonAlt) <a href="https://twitter.com/CryptoDonAlt/status/1856694227314311503?ref_src=twsrc%5Etfw">November 13, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Another trader, Mikybull Crypto, foresees a massive rally taking XRP to new all-time highs by March 2025.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> <br /><br />The train has left already<br /><br />Expect a massive rally to a new ath from now till March 2025. <a href="https://t.co/tmQ4bkWv3U">pic.twitter.com/tmQ4bkWv3U</a></p>
<p>&mdash; Mikybull &#x1f402;Crypto (@MikybullCrypto) <a href="https://twitter.com/MikybullCrypto/status/1857335680239652908?ref_src=twsrc%5Etfw">November 15, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Statistics:</strong> Santiment <a href="https://x.com/santimentfeed/status/1857139322614603835">data</a> reveals wallets holding at least 1 million XRP now control a combined 45.61 billion tokens, the highest since June 2018. Over the last two years, whales and sharks accumulated an additional 3.44 billion XRP, reflecting an 8.16% increase.</p>
<p><strong>What&#8217;s Next</strong>: The future of Ripple is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41999444/gary-genslers-departure-talk-fuels-xrp-meme-coin-play-powers-litecoin-as-action-shifts-to-lagging-altcoins">Gary Gensler&#8217;s Departure Talk Fuels XRP, &#8216;Meme Coin&#8217; Play Powers Litecoin As Action Shifts To Lagging Altcoins</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$ETH

$XRP

XRP Soars 58% On The Week: What Is Going On?

Biotech

General

ABUS

BRNS

Arbutus And Barinthus Bio Report IM-PROVE II Trial Data Showing Nivolumab Boosts HBsAg Loss Rates In Chronic Hepatitis B Patients; 23% Achieve HBsAg Loss By Week 48 With Imdusiran, VTP-300, And Low-Dose Nivolumab

<p>UBS  analyst Douglas Harter   maintains Apollo Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARI#NYSE">ARI</a>) with a Neutral and lowers the price target from $10 to $9.5.</p>


UBS Maintains Neutral on Apollo Comml Real Est, Lowers Price Target to $9.5

LGMK

LogicMark shares are trading lower after the company announced a 1-for-25 reverse stock split which will commence on November 19.

<p><i>– 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa –</i></p>
<p><i>– No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate –</i></p>
<p><i>– Late-breaking oral presentation of MARCH Part B study results at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting&#xAE; –</i></p>
<p>– <i>Key functional cure data from 24-week follow-up expected in Q2 2025 –</i></p>
<p>Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (&lt;1000 IU/mL) in both combination regimens. The efficacy and safety profile support continued development to evaluate the potential to achieve a functional cure. Detailed data will be presented in a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting<strong>&#xAE;</strong>, in San Diego, CA, on November 18 at 5:00 p.m. PT. Vir Biotechnology will host an investor conference call on November 19, at 5.15 a.m. PT / 8.15 a.m. ET.</p>
<p>Chronic hepatitis B (CHB) is a long-lasting, inflammatory liver disease caused by the hepatitis B virus (HBV)1. The World Health Organization estimates that 254 million people live with CHB, and an estimated 1.1 million yearly deaths are associated with the disease2. Complications from CHB may include liver cirrhosis, liver failure and liver cancer3. Although CHB can be treated, there is no cure1.</p>
<p>Participants in the trial received tobevibart and elebsiran alone (doublet regimen) or in combination with PEG-IFNα (triplet regimen). This analysis includes data from 51 participants in the doublet regimen arm and 27 participants in the triplet regimen arm at the end of treatment. Tobevibart was administered at 300 mg every 4 weeks; elebsiran, at 200 mg every 4 weeks; and PEG-IFNα at 180 µg weekly. Study primary endpoints include HBsAg seroclearance (defined as HBsAg below the lower limit of quantification) and treatment-emergent adverse events (TEAEs) at end of treatment. Secondary endpoints include anti-HBs seroconversion (defined as development of anti-HBs≥10 mIU/mL) at end of treatment.</p>
<p>The doublet and triplet regimens resulted in HBsAg loss at the end of treatment in 39% (7/18) and 46% (5/11) of participants with baseline HBsAg&lt;1,000 IU/mL, respectively. The proportion of participants with varying baseline HBsAg levels who achieved HBsAg loss at end of treatment was 16% (8/51) for the doublet and 22% (6/27) for the triplet regimen. The doublet regimen resulted in 50% (4/8) of participants who had achieved HBsAg loss also achieving anti-HBs seroconversion. All participants with HBsAg loss at the end of treatment who received the triplet regimen achieved anti-HBs seroconversion (100%, 6/6). Participants with HBsAg seroclearance at end of treatment who meet eligibility criteria will discontinue treatment. Functional cure assessment will occur 24 weeks after treatment discontinuation.</p>


Vir Biotechnology Announces End-Of-Treatment Results For Tobevibart And Elebsiran Combinations In Chronic Hepatitis B From The MARCH Study At AASLD The Liver Meeting

AVIR

Atea Pharmaceuticals Unveils New Data Supporting Bemnifosbuvir And Ruzasvir Combination For Hepatitis C Treatment At AASLD's Liver Meeting 2024; Phase 2 Findings Highlight Potential Efficacy

<p><i>Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids</i></p>
<p><i>Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome</i></p>
<p><i>Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025</i></p>
<p>GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8mpdWoq0vRuruY-wgKR7jeGdXm_k2idcer7Db_E2cxWdj4yekH1YRRXMjYkm08SS2fPpYVFEMZXywtJ8hQ3K1A==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a clinical-stage biopharmaceutical company, today presented new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting&#xAE; of the&nbsp;American Association for the Study of Liver Diseases. The data showed reductions in multiple classes of inflammatory lipid species associated with adverse cardiovascular outcomes. Pemvidutide is a balanced GLP-1/glucagon dual receptor agonist in development for the treatment of MASH and obesity.</p>
<p>The new data were derived from an analysis of plasma samples from subjects who completed a randomized placebo-controlled Phase 1b trial of pemvidutide in subjects with overweight or obesity and MASLD. In the Phase 1b clinical trial, 94 subjects with obesity or overweight and liver fat content (LFC) ≥10% were dosed 1:1:1:1 to pemvidutide (1.2mg, 1.8mg and 2.4mg) or placebo administered once-weekly subcutaneously for 12 weeks. In this study, pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment.</p>
<p>The goal of the study was to characterize changes in the lipid profile of patients before and after treatment with pemvidutide. In this study of 50 subjects, treatment with pemvidutide was shown to reduce plasma concentrations of atherogenic lipoproteins and lipotoxic lipid classes associated with MASH and implicated in cardiovascular and atherosclerotic disease. In particular, a rapid and significant reduction in small atherogenic LDL particles was observed in the 1.8 mg and 2.4 mg dose groups compared to placebo.</p>


Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024

GILD

Gilead's Livdelzi (Seladelpar) Shows Sustained Efficacy And Long-Term Safety In Primary Biliary Cholangitis; 81% Achieve Biochemical Response By Month 30, 41% Reach ALP Normalization, And 27% Experience Near Resolution Of Itch In Phase 3 ASSURE Study

AMZN

Amazon.com shares are trading lower after Third Point in a 13F filing disclosed that it decreased its stake in the company by 27%.

<p><i>-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction of liver stiffness by FibroScan&#xAE; (imaging fibrosis biomarker), and (3) 0.5 point decrease in ELFTM score (serum fibrosis biomarker) –</i></p>
<p><i>-- Analysis of biopsies by AI-based Digital Pathology (qFibrosis&#xAE;, Histoindex) corroborated the extent of improvement in fibrosis observed with conventional histopathology after 24 and 96 weeks of EFX treatment, including statistically significant reductions in fibrosis within the perisinusoidal and periportal zones of the liver –</i></p>
<p><i>-- 30% of participants receiving EFX 50mg for 96 weeks, compared to 0% for placebo, had almost complete reversal of MASH-related disease, as indicated by reversal of fibrosis to F≤1, resolution of steatohepatitis, and normalization of fat content to ≤5%</i></p>
<p>SOUTH SAN FRANCISCO, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced results of analyses supporting the clinical activity of efruxifermin (EFX) in metabolic dysfunction-associated steatohepatitis (MASH) in one oral presentation and two late-breaking poster presentations at&nbsp;the 75th&nbsp;Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting<strong>&#xAE;</strong>, held November 15-19, 2024, in San Diego.</p>


AKRO

Akero Therapeutics To Showcase New Analyses Of Phase 2b HARMONY Study In Presentations At 75th Annual AASLD The Liver Meeting 2024

<p>Throughout the last three months, 4 analysts have evaluated America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.43, along with a high estimate of $20.80 and a low estimate of $17.30. Experiencing a 6.07% decline, the current average is now lower than the previous average price target of $19.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731686464_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of America Movil by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitor Tomita</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.80</td>
<td>$20.80</td>
</tr>
<tr>
<td>Andres Coello</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$17.30</td>
<td>$17.80</td>
</tr>
<tr>
<td>Vitor Tomita</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.80</td>
<td>$21.00</td>
</tr>
<tr>
<td>Andres Coello</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$17.80</td>
<td>$18.90</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to America Movil. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of America Movil compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of America Movil's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into America Movil's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AMX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on America Movil analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind America Movil</h2>
<p>America Movil is the largest telecom carrier in Latin America, serving about 290 million wireless customers across the region. It also provides fixed-line phone, internet access, and television services in most of the countries it serves. Mexico is the firm's largest market, providing about 35% of service revenue. Movil dominates the Mexican wireless market with more than 60% customer share and also serves about half of fixed-line internet access customers in the country. Brazil, its second most important market, provides about 20% of service revenue. Movil sold its low-margin wireless resale business in the US to Verizon in 2021 and now owns a 1.4% stake in the US telecom giant. The firm also holds a 60% stake in Telekom Austria.</p>
<h3>America Movil's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, America Movil showcased positive performance, achieving a revenue growth rate of <strong>9.62%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> America Movil's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>2.88%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> America Movil's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.44%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> America Movil's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.37%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> America Movil's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.59</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down America Movil: 4 Analysts Share Their Views

<p>In the current session, <strong>ASML Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)</strong> is trading at $670.94, after a <strong>3.18%</strong> decrease. Over the past month, the stock fell by <strong>7.12%</strong>, and in the past year, by <strong>3.25%</strong>. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1731686463_0.png" alt="Past Year Chart" /></p>

<h3>ASML Holding P/E Ratio Analysis in Relation to Industry Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of the <strong>84.99</strong> in the Semiconductors &amp; Semiconductor Equipment industry, ASML Holding Inc. has a lower P/E ratio of <strong>37.09</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1731686463_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

ASML

P/E Ratio Insights for ASML Holding

<p>Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">15</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $46.87, along with a high estimate of $67.00 and a low estimate of $38.00. A decline of 16.09% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731686456_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of Advance Auto Parts by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Scott Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$39.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$46.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Scott Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$67.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Scott Stember</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Neutral</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$56.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Scott Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$46.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$60.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Max Rakhlenko</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Advance Auto Parts. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Advance Auto Parts compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Advance Auto Parts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Advance Auto Parts's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AAP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Advance Auto Parts analyst ratings.</strong></a></p>
<h2>Delving into Advance Auto Parts's Background</h2>
<p>Advance Auto Parts is a leading auto parts retailer in North America with more than 5,000 store and branch locations. About 60% of the firm's sales are geared toward the professional channel, with the remaining 40% going to the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units conducive to various vehicle makes and models. The retailer primarily competes on the basis of inventory availability and service speed, making the operating efficiency of its hub and spoke distribution model critical to meeting customer needs.</p>
<h3>Advance Auto Parts: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Advance Auto Parts's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-0.11%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>1.68%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Advance Auto Parts's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.73%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Advance Auto Parts's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.37%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Advance Auto Parts's debt-to-equity ratio is below the industry average. With a ratio of <b>1.52</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 15 Analyst Recommendations For Advance Auto Parts

<p>UBS  analyst Shneur Gershuni   maintains Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Buy and raises the price target from $55 to $70.</p>


UBS Maintains Buy on Williams Companies, Raises Price Target to $70

<p>Analysts' ratings for JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for JD.com, revealing an average target of $45.0, a high estimate of $50.00, and a low estimate of $28.00. This current average has increased by 7.58% from the previous average price target of $41.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731686445_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive JD.com is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fawne Jiang</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Gregory Zhao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andre Chang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Fawne Jiang</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to JD.com. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of JD.com compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into JD.com's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/JD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on JD.com analyst ratings.</strong></a></p>
<h2>Delving into JD.com's Background</h2>
<p>JD.com is a leading e-commerce platform with its 2022 China GMV being similar to Pinduoduo (GMV not reported), on our estimate, but still lower than Alibaba. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.</p>
<h3>Financial Insights: JD.com</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> JD.com's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>1.2%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> JD.com's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.34%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> JD.com's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.71%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> JD.com's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.02%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> JD.com's debt-to-equity ratio is below the industry average. With a ratio of <b>0.39</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


6 Analysts Assess JD.com: What You Need To Know

<p>i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-18. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that i3 Verticals will report an <strong>earnings per share</strong> (EPS) of $0.20.</p>
<p>i3 Verticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS missed by $0.29, leading to a 7.47% drop in the share price on the subsequent day.</p>
<p>Here's a look at i3 Verticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.36</td>
<td>0.38</td>
<td>0.36</td>
<td>0.4</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.07</td>
<td>0.34</td>
<td>0.36</td>
<td>0.4</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>-10.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731686439_0.png" alt="eps graph" /></p>
<h3>i3 Verticals Share Price Analysis</h3>
<p>Shares of i3 Verticals were trading at $24.87 as of November 14. Over the last 52-week period, shares are up 19.95%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on i3 Verticals</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on i3 Verticals.</p>
<p>A total of 4 analyst ratings have been received for i3 Verticals, with the consensus rating being Buy. The average one-year price target stands at $29.5, suggesting a potential 18.62% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Cantaloupe, IntL Money Express and Repay Holdings, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Cantaloupe, with an average 1-year price target of $10.67, suggesting a potential 57.1% downside.</li>
<li>Analysts currently favor an Buy trajectory for IntL Money Express, with an average 1-year price target of $27.5, suggesting a potential 10.57% upside.</li>
<li>Repay Holdings is maintaining an Buy status according to analysts, with an average 1-year price target of $13.0, indicating a potential 47.73% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Cantaloupe, IntL Money Express and Repay Holdings are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>i3 Verticals</td>
<td>Buy</td>
<td>-2.14%</td>
<td>$51.31M</td>
<td>-3.02%</td>
</tr>
<tr>
<td>Cantaloupe</td>
<td>Outperform</td>
<td>13.01%</td>
<td>$28.85M</td>
<td>1.78%</td>
</tr>
<tr>
<td>IntL Money Express</td>
<td>Buy</td>
<td>-0.28%</td>
<td>$60.60M</td>
<td>12.17%</td>
</tr>
<tr>
<td>Repay Holdings</td>
<td>Buy</td>
<td>4.35%</td>
<td>$58.59M</td>
<td>-0.50%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>i3 Verticals is at the bottom for Revenue Growth and Gross Profit, with negative values for both metrics. It is also at the bottom for Return on Equity. Overall, i3 Verticals is performing less favorably compared to its peers in terms of financial metrics.</p>
<h3>Delving into i3 Verticals's Background</h3>
<p>i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Merchant Services and Software and Services. The company generates maximum revenue from the Software and Services segment. The company's strategic vertical market includes schools, the public sector, not-for-profit organizations, healthcare and others. It provides various solutions such as, gateway, payment processing, online payment, Document management, and ERP among others.</p>
<h3>Financial Milestones: i3 Verticals's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> i3 Verticals's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-2.14%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-13.46%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> i3 Verticals's ROE excels beyond industry benchmarks, reaching <strong>-3.02%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> i3 Verticals's ROA excels beyond industry benchmarks, reaching <strong>-0.87%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.54</strong>.</p>
<p><a href="https://www.benzinga.com/quote/IIIV/earnings"><strong>To track all earnings releases for i3 Verticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


IIIV

Earnings Preview For i3 Verticals

<p>PNC Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $206.44, a high estimate of $235.00, and a low estimate of $180.00. This upward trend is apparent, with the current average reflecting a 4.73% increase from the previous average price target of $197.11.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731686427_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive PNC Finl Servs Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$229.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Underperform</td>
<td>$182.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$180.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$212.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$189.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to PNC Finl Servs Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of PNC Finl Servs Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of PNC Finl Servs Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of PNC Finl Servs Gr's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PNC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on PNC Finl Servs Gr analyst ratings.</strong></a></p>
<h2>About PNC Finl Servs Gr</h2>
<p>PNC Financial Services Group is a diversified financial services company offering retail banking, corporate and institutional banking, asset management, and residential mortgage banking across the United States.</p>
<h3>PNC Finl Servs Gr's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> PNC Finl Servs Gr's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>3.78%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>25.7%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> PNC Finl Servs Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>2.58%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> PNC Finl Servs Gr's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.25%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> PNC Finl Servs Gr's debt-to-equity ratio is below the industry average at <strong>1.22</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 9 Analyst Recommendations For PNC Finl Servs Gr

iShares iBonds Dec 2030 Term USD Corp UCITS ETF USD (Acc)

Comments

(ISBNF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO